A dipeptide derivative as formyl peptide receptor 1 (FPR1) antagonist is provided. The dipeptide derivative is represented by formula (I), wherein:
the chiral centers in formula (I) are S and R configurations respectively; each of RK and RT is selected from a group consisting of a hydrogen, a hydroxyl group, a C
1
-C
4
alkyl-substituted hydroxyl group, a C
1
-C
4
alkoxyl group, a carboxylic acid group, a C
1
-C
4
alkyl nitrile-substituted, C
1
-C
4
alkyl-substituted or C
1
-C
4
alkoxyl-substituted amido group, a C
1
-C
4
alkyl-substituted ester group and a benzoyl group having a C
1
-C
4
alkyl-substituted benzene ring; and each of RM and RS is selected from a group consisting of a hydrogen, a hydroxyl group, a phenyl group, a pyridinyl group, a carboxylic acid group, a C
1
-C
4
alkoxyl substituted ester group, and a benzoyl group having a hydroxyl-substituted, a halogen-substituted, a C
1
-C
4
alkoxyl-substituted or a C
1
-C
4
alkyl-substituted benzene ring.
relationship studies concluded that the fragment N-benzoyl-Trp-Phe-OMe (3) was most suitable as a core structure for interaction with FPR1, and may be approved as a lead for the development of new drugs in the treatment of neutrophilic inflammatory diseases. As some of the synthesized compounds exhibited separable conformational isomers, and showed diverse bioactivities, the conformationanalysis of these